A citation-based method for searching scientific literature

Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, Benjamin J Solomon, Gregory J Riely, Myung-Ju Ahn, Caicun Zhou, S Martin Shreeve, Paulina Selaru, Anna Polli, Patrick Schnell, Keith D Wilner, Robin Wiltshire, D Ross Camidge, Lucio Crinò. J Clin Oncol 2015
Times Cited: 409







List of co-cited articles
764 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Siow Ming Lee, Conrad R Lewanski, Nicholas Counsell, Christian Ottensmeier, Andrew Bates, Nirali Patel, Christina Wadsworth, Yenting Ngai, Allan Hackshaw, Corinne Faivre-Finn. J Natl Cancer Inst 2014
84
7

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
6

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Paul W Sperduto, Meihua Wang, H Ian Robins, Michael C Schell, Maria Werner-Wasik, Ritsuko Komaki, Luis Souhami, Mark K Buyyounouski, Deepak Khuntia, William Demas,[...]. Int J Radiat Oncol Biol Phys 2013
187
6

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
James W Welsh, Ritsuko Komaki, Arya Amini, Mark F Munsell, Wyatt Unger, Pamela K Allen, Joe Y Chang, Jeffrey S Wefel, Susan L McGovern, Linda L Garland,[...]. J Clin Oncol 2013
282
6

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
6

Recent trends in epidemiology of brain metastases: an overview.
Emeline Tabouret, Olivier Chinot, Philippe Metellus, Agnès Tallet, Patrice Viens, Anthony Gonçalves. Anticancer Res 2012
168
6

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Thomas Bachelot, Gilles Romieu, Mario Campone, Véronique Diéras, Claire Cropet, Florence Dalenc, Marta Jimenez, Emilie Le Rhun, Jean-Yves Pierga, Anthony Gonçalves,[...]. Lancet Oncol 2013
387
6

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Makoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Tomohiro Tanaka, Hiroshi Kuriki, Ali Zeaiter, Tomohide Tamura. Lung Cancer 2018
36
16

Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.
Vinai Gondi, Stephanie L Pugh, Wolfgang A Tome, Chip Caine, Ben Corn, Andrew Kanner, Howard Rowley, Vijayananda Kundapur, Albert DeNittis, Jeffrey N Greenspoon,[...]. J Clin Oncol 2014
546
6

A randomized trial of surgery in the treatment of single metastases to the brain.
R A Patchell, P A Tibbs, J W Walsh, R J Dempsey, Y Maruyama, R J Kryscio, W R Markesbery, J S Macdonald, B Young. N Engl J Med 1990
6

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
6

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
James Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, Shirish Gadgeel, Leena Gandhi, Dong-Wan Kim, Fabrice Barlesi, Ramaswamy Govindan, Anne-Marie C Dingemans, Lucio Crino,[...]. J Thorac Oncol 2017
45
13

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
6


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
6

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
6

Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Kentaro Ito, Osamu Hataji, Hiroyasu Kobayashi, Atsushi Fujiwara, Masamichi Yoshida, Corina N D'Alessandro-Gabazza, Hidetoshi Itani, Motoaki Tanigawa, Takuya Ikeda, Kentaro Fujiwara,[...]. J Thorac Oncol 2017
35
17

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Jin-Ji Yang, Caicun Zhou, Yisheng Huang, Jifeng Feng, Sun Lu, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng,[...]. Lancet Respir Med 2017
95
6

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Linda Chen, Jacqueline Douglass, Lawrence Kleinberg, Xiaobu Ye, Ariel E Marciscano, Patrick M Forde, Julie Brahmer, Evan Lipson, William Sharfman, Hans Hammers,[...]. Int J Radiat Oncol Biol Phys 2018
118
6

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Yi-Long Wu, Myung-Ju Ahn, Marina Chiara Garassino, Ji-Youn Han, Nobuyuki Katakami, Hye Ryun Kim, Rachel Hodge, Paramjit Kaur, Andrew P Brown, Dana Ghiorghiu,[...]. J Clin Oncol 2018
167
6

Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.
Jill S Barnholtz-Sloan, Andrew E Sloan, Faith G Davis, Fawn D Vigneau, Ping Lai, Raymond E Sawaya. J Clin Oncol 2004
885
6

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
507
6

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
431
6

Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw. Cancer Discov 2017
222
6

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
6

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Todd M Bauer, Alice T Shaw, Melissa L Johnson, Alejandro Navarro, Justin F Gainor, Holger Thurm, Yazdi K Pithavala, Antonello Abbattista, Gerson Peltz, Enriqueta Felip. Target Oncol 2020
22
27

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Leora Horn, Jennifer G Whisenant, Heather Wakelee, Karen L Reckamp, Huan Qiao, Ticiana A Leal, Liping Du, Jennifer Hernandez, Vincent Huang, George R Blumenschein,[...]. J Thorac Oncol 2019
47
12

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
38
15

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
455
6

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
48
12

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
93
6

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney,[...]. Lancet Oncol 2011
675
5

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Fiona Blackhall, D Ross Camidge, Alice T Shaw, Jean-Charles Soria, Benjamin J Solomon, Tony Mok, Vera Hirsh, Pasi A Jänne, Yuankai Shi, Pan-Chyr Yang,[...]. ESMO Open 2017
45
11

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
361
5

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Sai-Hong Ignatius Ou, Michele Azada, David J Hsiang, June M Herman, Tatiana S Kain, Christina Siwak-Tapp, Cameron Casey, Jie He, Siraj M Ali, Samuel J Klempner,[...]. J Thorac Oncol 2014
125
5


Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Georgina V Long, Uwe Trefzer, Michael A Davies, Richard F Kefford, Paolo A Ascierto, Paul B Chapman, Igor Puzanov, Axel Hauschild, Caroline Robert, Alain Algazi,[...]. Lancet Oncol 2012
601
5

Brain tumor mutations detected in cerebral spinal fluid.
Wenying Pan, Wei Gu, Seema Nagpal, Melanie Hayden Gephart, Stephen R Quake. Clin Chem 2015
146
5

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.
Leticia De Mattos-Arruda, Regina Mayor, Charlotte K Y Ng, Britta Weigelt, Francisco Martínez-Ricarte, Davis Torrejon, Mafalda Oliveira, Alexandra Arias, Carolina Raventos, Jiabin Tang,[...]. Nat Commun 2015
332
5

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.
Elena I Pentsova, Ronak H Shah, Jiabin Tang, Adrienne Boire, Daoqi You, Samuel Briggs, Antonio Omuro, Xuling Lin, Martin Fleisher, Christian Grommes,[...]. J Clin Oncol 2016
171
5

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Y S Li, B Y Jiang, J J Yang, X C Zhang, Z Zhang, J Y Ye, W Z Zhong, H Y Tu, H J Chen, Z Wang,[...]. Ann Oncol 2018
86
5

Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Sara Redaelli, Monica Ceccon, Marina Zappa, Geeta G Sharma, Cristina Mastini, Mario Mauri, Marion Nigoghossian, Luca Massimino, Nicoletta Cordani, Francesca Farina,[...]. Cancer Res 2018
28
17

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Adam S Crystal, Alice T Shaw, Lecia V Sequist, Luc Friboulet, Matthew J Niederst, Elizabeth L Lockerman, Rosa L Frias, Justin F Gainor, Arnaud Amzallag, Patricia Greninger,[...]. Science 2014
441
5

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
David W Andrews, Charles B Scott, Paul W Sperduto, Adam E Flanders, Laurie E Gaspar, Michael C Schell, Maria Werner-Wasik, William Demas, Janice Ryu, Jean-Paul Bahary,[...]. Lancet 2004
5

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
5

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Ryohei Katayama, Tahsin M Khan, Cyril Benes, Eugene Lifshits, Hiromichi Ebi, Victor M Rivera, William C Shakespeare, A John Iafrate, Jeffrey A Engelman, Alice T Shaw. Proc Natl Acad Sci U S A 2011
399
5

Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
Ying Dai, Quanxiang Wei, Christian Schwager, Mahmoud Moustafa, Cheng Zhou, Kenneth E Lipson, Wilko Weichert, Jürgen Debus, Amir Abdollahi. Radiother Oncol 2015
26
19

Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.
Anita Mahajan, Salmaan Ahmed, Mary Frances McAleer, Jeffrey S Weinberg, Jing Li, Paul Brown, Stephen Settle, Sujit S Prabhu, Frederick F Lang, Nicholas Levine,[...]. Lancet Oncol 2017
247
5

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Wei-Sheng Huang, Shuangying Liu, Dong Zou, Mathew Thomas, Yihan Wang, Tianjun Zhou, Jan Romero, Anna Kohlmann, Feng Li, Jiwei Qi,[...]. J Med Chem 2016
142
5

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib.
Thomas Lee Collier, Marc D Normandin, Nickeisha A Stephenson, Eli Livni, Steven H Liang, Dustin W Wooten, Shadi A Esfahani, Michael G Stabin, Umar Mahmood, Jianqing Chen,[...]. Nat Commun 2017
24
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.